SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?

被引：0
|
作者：
Mahmoud Al Rifai
L. Kristin Newby
Ajith P. Nair
Arunima Misra
Joseph G. Rogers
Savitri Fedson
Salim S. Virani
机构：
[1] Baylor College of Medicine,Section of Cardiology, Department of Medicine
[2] Duke University School of Medicine,Department of Medicine, Division of Cardiology
[3] Duke University School of Medicine,Duke Clinical Research Institute
[4] Texas Heart Institute,Division of Cardiology
[5] Section of Cardiology,undefined
[6] Michael E. DeBakey Veterans Affairs Medical Center,undefined
来源：
Current Atherosclerosis Reports | 2022年 / 24卷
关键词：
Sodium-glucose cotransporter-2 inhibitors (SGLT-2i); Heart failure (HF); Heart failure with preserved ejection fraction (HFpEF); Heart failure with reduced ejection fraction (HFrEF);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：627 / 634
页数：7
相关论文
共 50 条
  • [31] Lessons from SGLT-2 inhibitors: rethinking endpoints for heart failure studies
    Sheng Fu
    Sheldon E. Litwin
    Ryan J. Tedford
    Nature Medicine, 2021, 27 : 1872 - 1873
  • [32] SGLT-2 inhibitors in heart failure: Time for broader eligibility and earlier initiation
    Ferro, Enrico G.
    Pitt, Bertram
    Bhatt, Deepak L.
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2021, 88 (11) : 601 - 606
  • [33] EMPULSE trial: Time to use SGLT-2 inhibitors in acute heart failure?
    Roy, Shubhajeet
    Saxena, Mehul
    Pradhan, Akshyaya
    NATIONAL MEDICAL JOURNAL OF INDIA, 2024, 37 (02): : 93 - 94
  • [34] CARDIOVASCULAR DISEASE SGLT-2 inhibitors in heart failure: a new therapeutic avenue
    Vaduganathan, Muthiah
    Butler, Javed
    NATURE MEDICINE, 2019, 25 (11) : 1653 - 1654
  • [35] ADHERENCE TO SGLT-2 INHIBITORS ACROSS THE SPECTRUM OF HEART FAILURE: A SOCIOECONOMIC DISPARITY?
    Somoza-Cano, Francisco J.
    Sakamuri, Laxmi
    Amoah, Joseph
    Pineda, Allan Bueso
    Houry, Ahmad
    Argueta, Allan Santos
    Velasquez, Adolfo
    Mogollon, Ivan
    Mantilla, Diego Andres Padilla
    Somoza, Francisco Ramon
    Ravakhah, Keyvan
    CHEST, 2024, 166 (04) : 579A - 580A
  • [36] Lessons from SGLT-2 inhibitors: rethinking endpoints for heart failure studies
    Fu, Sheng
    Litwin, Sheldon E.
    Tedford, Ryan J.
    NATURE MEDICINE, 2021, 27 (11) : 1872 - 1873
  • [37] Expect the Unexpected: SGLT-2 Inhibitors in the Treatment of Type 2 Diabetes and/or Heart Failure
    Seferovic, Jelena P.
    Seferovic, Petar M.
    CARDIOLOGY, 2020, 145 (05) : 321 - 323
  • [38] SGLT2 inhibitors in acute decompensated heart failure, what do we know?
    Lapteva, Anastasiya E.
    Nasonova, Svetlana N.
    Zhirov, Igor, V
    Tereshchenko, Sergey N.
    TERAPEVTICHESKII ARKHIV, 2022, 94 (04) : 565 - 571
  • [39] Heart Failure Risk Prediction Models What Have We Learned?
    Levy, Wayne C.
    Anand, Inder S.
    JACC-HEART FAILURE, 2014, 2 (05) : 437 - 439
  • [40] Six lessons learned from the use of SGLT2 inhibitors in patients with heart failure
    Packer, Milton
    NATURE REVIEWS CARDIOLOGY, 2022, 19 (08) : 499 - 500
12345